Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004055068 | SCV002685775 | uncertain significance | not specified | 2025-02-18 | criteria provided, single submitter | clinical testing | The c.1274A>G (p.D425G) alteration is located in exon 12 (coding exon 12) of the PRKDC gene. This alteration results from a A to G substitution at nucleotide position 1274, causing the aspartic acid (D) at amino acid position 425 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003103569 | SCV002932100 | uncertain significance | Severe combined immunodeficiency due to DNA-PKcs deficiency | 2022-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 425 of the PRKDC protein (p.Asp425Gly). This variant is present in population databases (rs752106941, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with PRKDC-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |